BioRestorative Therapies, Inc. carries no debt; cash flow comfortably covers obligations.

BioRestorative Therapies, Inc.'s free cash flow has decreased 30.81% from $-8.34M last year to $-10.91M, signaling decreasing performance

BioRestorative Therapies, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

BioRestorative Therapies, Inc. has insufficient data to evaluate this check.

BioRestorative Therapies, Inc. has a net cash position, so leverage is healthy.

BioRestorative Therapies, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BioRestorative Therapies, Inc.'s profit margin has decreased (37.97%) in the last year from -2.24K% to -3.09K%, signaling decreasing performance

BioRestorative Therapies, Inc.'s short-term liabilities of $3.72M exceed its short-term assets of $3.14M, signaling financial risk

BioRestorative Therapies, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioRestorative Therapies, Inc.'s return on equity of -423.84%, is lower than 15.00%, indicating bad performance

BioRestorative Therapies, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioRestorative Therapies, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

BioRestorative Therapies, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BioRestorative Therapies, Inc. has negative free cash flow, indicating cash burn

BioRestorative Therapies, Inc.'s yearly earnings has decreased 58.61% since last year from $-8.98M to $-14.24M, signaling decreasing performance

BioRestorative Therapies, Inc.'s yearly revenue has decreased 10.30% since last year from $401.00K to $359.70K, signaling decreasing performance

ROIC -464.86% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioRestorative Therapies, Inc.'s 3-year revenue CAGR of 44.27% is positive, indicating growing revenue over the past 3 years

BioRestorative Therapies, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

BioRestorative Therapies, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BioRestorative Therapies, Inc. has insufficient data to evaluate this check.

BioRestorative Therapies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioRestorative Therapies, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioRestorative Therapies, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioRestorative Therapies, Inc. has insufficient data to evaluate this check.

BioRestorative Therapies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioRestorative Therapies, Inc. has a price-to-book ratio of 0.60x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioRestorative Therapies, Inc. has a price-to-sales ratio of 5.05x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue